Author: Vigilare Biopharma

  • Home
  • Vigilare Biopharma
New Device Cybersecurity Expectations Device Compliance in 2026

New Device Cybersecurity Expectations Device Compliance in 2026

Given the abundance of connected devices, cloud-linked systems, software-driven platforms, and their ability to pose direct risks to patient safety, data integrity, and product reliability, Cybersecurity has now become more than a compliance issue. From

Read More
Pharmacovigilance Mandates and Regulations in India Key Insights about the CDSCO Framework

Pharmacovigilance Mandates and Regulations in India Key Insights about the CDSCO Framework

India’s pharmaceutical market continues to expand, and with the growth comes greater responsibility for drug safety oversight. The Central Drugs Standard Control Organization (CDSCO) plays a central role in shaping the country’s pharmacovigilance framework. Key

Read More
The Rising Bar of the Indian Pharma Sector

The Rising Bar of the Indian Pharma Sector Regulatory Readiness for Foreign Manufacturers

India’s pharmaceutical sector is evolving from high-volume output to strategic global importance. The domestic market, currently USD 50–60 billion, is projected to reach USD 130 billion by 2030. With FY2026 growth forecasts of 7%–11%, India

Read More

Why Expert MOH Interaction and Regulatory Liaison Support Matter?

MOH interaction and health authority liaison have become critical differentiators for medical device manufacturers navigating diverse, regulated, and fast-evolving regulatory landscapes. Every country’s Ministry of Health (MOH) or equivalent health agency expects precise documentation, consistent

Read More

Pharmacovigilance Submission Documents in the United States

Globally, Pharmacovigilance (PV) is built on one central idea: the benefit–risk evaluation should not stop at approval; it must continue through the full drug development regulatory process and the product’s commercial lifecycle. It is no

Read More

Why Regulatory Affairs is Central to Drug Development?

Ideating, researching, and developing a drug or biologic product and bringing it to market is not a simple process. From preclinical discovery through market authorization, every stage of the drug lifecycle is critical. Across the

Read More

FDA Launches TEMPO What Medical Device Innovators Need to Know

Are you a medical device manufacturer working on digital therapeutics, remote monitoring tools, or AI-enabled care solutions for chronic disease management? If your innovation is outcome-based and driven by real-world data, you should pay close

Read More

Pharmacovigilance Submission Documents in the Europe Region

In Europe, Pharmacovigilance is heavily dependent on submitted documents. Each core submission enables regulators to assess how data has been maintained throughout the product life cycle. This approach minimizes risks. A robust safety system can

Read More

What is Pharmacovigilance (PV) and Why Is It Important?

Despite being an established practice in the pharmaceutical industry, the question ‘What is Pharmacovigilance?’ remains a frequently asked one among the general public, students, and healthcare professionals, including doctors and nurses, in developing regions.  Whether

Read More

MAHs and PV Audit Readiness 2026

Stepping into 2026, the challenge for marketing authorization holders (MAHs) is not only to address AI intrusion into pharmacovigilance but also to ensure their existing pharmacovigilance systems are compliant, all-through, controlled, data-driven, and inspection-ready for

Read More